Impact on health-related quality of life of the addition of bevacizumab to first-line chemotherapy for ovarian cancer

 

Authors

  • M. Di Maio Clinical Trials Unit, Istituto Nazionale Tumori IRCCS – “Fondazione G. Pascale”, Napoli, Italy.
  • G. Daniele Clinical Trials Unit, Istituto Nazionale Tumori IRCCS – “Fondazione G. Pascale”, Napoli, Italy.
  • M.C. Piccirillo Clinical Trials Unit, Istituto Nazionale Tumori IRCCS – “Fondazione G. Pascale”, Napoli, Italy.

Abstract

No abstract available